Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of...
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Patients with Major Depressive Disorder Have Increased Triglyceride Levels
A meta-analysis found elevated triglyceride levels in MDD patients, suggesting a link to cardiovascular events. Triglyceride levels were near the upper normal limit in MDD patients compared to controls, with significant differences influenced by age, BMI, and drug use.
How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression
Paul Stamets advocates for the respectful use of psilocybin mushrooms, emphasizing their therapeutic potential for conditions like treatment-resistant depression, PTSD, and cluster headaches. Clinical trials have shown psilocybin's effectiveness, leading to FDA recognition as a breakthrough medicine. Psychedelics enhance brain connectivity and neuroplasticity, potentially offering long-term benefits. However, microdosing's efficacy remains scientifically unproven, and psychedelic use carries risks, including potential for psychosis in vulnerable individuals. Researchers aim to develop non-psychedelic alternatives to harness these benefits.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath